Literature DB >> 11113006

Malignant hypertrophic cardiomyopathy caused by the Arg723Gly mutation in beta-myosin heavy chain gene.

M Enjuto1, A Francino, F Navarro-López, D Viles, J C Paré, A M Ballesta.   

Abstract

Mutations causing hypertrophic cardiomyopathy have been described in nine genes encoding sarcomeric proteins. We report a new mutation in three families, with a C-->G transversion in nucleotide 12 307 of the beta-myosin heavy chain gene, located at the essential light chain interacting region, resulting in the replacement of arginine by glycine at amino acid residue 723. PCR amplification of the selected regions followed by single strand conformation polymorphism analysis, DNA sequencing of the polymorphic patterns and restriction analysis were used to detect the mutation. A total of 23 individuals were diagnosed as carriers, and seven were obligate carriers or had been clinically diagnosed. The Arg723Gly mutation was associated with a malignant phenotype. Ten out of 30 affected members died suddenly or needed an implantable cardioverter-defibrillator at a mean age of 42, and seven members developed progressive heart failure, leading to death or heart transplant in five, at a mean age of 50 years. Echocardiography showed non-obstructive left ventricular hypertrophy in affected members older than 20 (sensitivity 68%). Mean survival of affected members was 51 years. In conclusion, a new mutation Arg723Gly in beta-myosin heavy chain gene is reported which shortens life expectancy because of sudden death and end-stage heart failure. Copyright 2000 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11113006     DOI: 10.1006/jmcc.2000.1260

Source DB:  PubMed          Journal:  J Mol Cell Cardiol        ISSN: 0022-2828            Impact factor:   5.000


  16 in total

1.  Mutation of the myosin converter domain alters cross-bridge elasticity.

Authors:  Jan Köhler; Gerhard Winkler; Imke Schulte; Tim Scholz; William McKenna; Bernhard Brenner; Theresia Kraft
Journal:  Proc Natl Acad Sci U S A       Date:  2002-03-19       Impact factor: 11.205

2.  Cardiomyopathy mutations reveal variable region of myosin converter as major element of cross-bridge compliance.

Authors:  B Seebohm; F Matinmehr; J Köhler; A Francino; F Navarro-Lopéz; A Perrot; C Ozcelik; W J McKenna; B Brenner; T Kraft
Journal:  Biophys J       Date:  2009-08-05       Impact factor: 4.033

3.  Converter domain mutations in myosin alter structural kinetics and motor function.

Authors:  Laura K Gunther; John A Rohde; Wanjian Tang; Shane D Walton; William C Unrath; Darshan V Trivedi; Joseph M Muretta; David D Thomas; Christopher M Yengo
Journal:  J Biol Chem       Date:  2018-12-05       Impact factor: 5.157

Review 4.  Precision medicine approach to genetic cardiomyopathy.

Authors:  K Filonenko; H A Katus; B Meder
Journal:  Herz       Date:  2017-08       Impact factor: 1.443

Review 5.  Mutation type is not clinically useful in predicting prognosis in hypertrophic cardiomyopathy.

Authors:  Andrew P Landstrom; Michael J Ackerman
Journal:  Circulation       Date:  2010-12-07       Impact factor: 29.690

6.  The urinary bladder of spontaneously hypertensive rat demonstrates bladder hypertrophy, inflammation, and fibrosis but not hyperplasia.

Authors:  Shanwei Shen; Chun-Mei Xia; Li-Ya Qiao
Journal:  Life Sci       Date:  2014-10-30       Impact factor: 5.037

7.  Unequal allelic expression of wild-type and mutated β-myosin in familial hypertrophic cardiomyopathy.

Authors:  Snigdha Tripathi; Imke Schultz; Edgar Becker; Judith Montag; Bianca Borchert; Antonio Francino; Francisco Navarro-Lopez; Andreas Perrot; Cemil Özcelik; Karl-Josef Osterziel; William J McKenna; Bernhard Brenner; Theresia Kraft
Journal:  Basic Res Cardiol       Date:  2011-07-19       Impact factor: 17.165

8.  Cardiomyopathy mutations impact the actin-activated power stroke of human cardiac myosin.

Authors:  Wanjian Tang; Jinghua Ge; William C Unrath; Rohini Desetty; Christopher M Yengo
Journal:  Biophys J       Date:  2021-04-20       Impact factor: 3.699

Review 9.  Hypertrophic cardiomyopathy: how do mutations lead to disease?

Authors:  Júlia Daher Carneiro Marsiglia; Alexandre Costa Pereira
Journal:  Arq Bras Cardiol       Date:  2014-03       Impact factor: 2.000

10.  A novel Myosin essential light chain mutation causes hypertrophic cardiomyopathy with late onset and low expressivity.

Authors:  Paal Skytt Andersen; Paula Louise Hedley; Stephen P Page; Petros Syrris; Johanna Catharina Moolman-Smook; William John McKenna; Perry Mark Elliott; Michael Christiansen
Journal:  Biochem Res Int       Date:  2012-04-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.